Replimune Group (NASDAQ:REPL) Reaches New 52-Week High – Time to Buy?

Replimune Group, Inc. (NASDAQ:REPL) shares hit a new 52-week high on Thursday . The company traded as high as $13.90 and last traded at $12.86, with a volume of 6196951 shares. The stock had previously closed at $11.83.

Analyst Upgrades and Downgrades

Several research analysts have commented on REPL shares. Wall Street Zen upgraded shares of Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. HC Wainwright restated a “sell” rating on shares of Replimune Group in a research report on Monday, April 13th. Wolfe Research raised shares of Replimune Group to an “outperform” rating in a research note on Tuesday. Cantor Fitzgerald cut shares of Replimune Group from an “overweight” rating to a “hold” rating in a research report on Monday, April 13th. Finally, JPMorgan Chase & Co. raised shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $17.00 target price on the stock in a research note on Friday, June 26th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Replimune Group currently has an average rating of “Moderate Buy” and an average price target of $11.43.

Replimune Group Stock Up 8.7%

The business’s 50 day simple moving average is $9.92 and its 200-day simple moving average is $7.47. The company has a market cap of $1.08 billion, a price-to-earnings ratio of -3.80 and a beta of 0.88. The company has a debt-to-equity ratio of 0.63, a quick ratio of 4.79 and a current ratio of 4.79.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). Sell-side analysts expect that Replimune Group, Inc. will post -2.54 earnings per share for the current year.

Insider Buying and Selling

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.24, for a total value of $110,880.00. Following the transaction, the insider directly owned 180,962 shares of the company’s stock, valued at $1,672,088.88. This represents a 6.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Replimune Group

Large investors have recently made changes to their positions in the company. Balyasny Asset Management L.P. raised its holdings in shares of Replimune Group by 507.4% during the 3rd quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock valued at $11,012,000 after purchasing an additional 2,195,448 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in shares of Replimune Group during the 4th quarter worth about $17,568,000. Commodore Capital LP acquired a new position in shares of Replimune Group during the 4th quarter valued at about $13,851,000. EcoR1 Capital LLC bought a new position in shares of Replimune Group in the 1st quarter valued at approximately $7,650,000. Finally, JPMorgan Chase & Co. raised its stake in shares of Replimune Group by 2,333.6% in the 4th quarter. JPMorgan Chase & Co. now owns 925,173 shares of the company’s stock valued at $8,993,000 after acquiring an additional 887,157 shares in the last quarter. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.